WO2006068899A2 - Preserved ophthalmic compositions comprising aloe vera - Google Patents
Preserved ophthalmic compositions comprising aloe vera Download PDFInfo
- Publication number
- WO2006068899A2 WO2006068899A2 PCT/US2005/045247 US2005045247W WO2006068899A2 WO 2006068899 A2 WO2006068899 A2 WO 2006068899A2 US 2005045247 W US2005045247 W US 2005045247W WO 2006068899 A2 WO2006068899 A2 WO 2006068899A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- preservative
- group
- aloe vera
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- US Patent No. 4,788,007 to Baron discloses a method of using ophthalmic dosage of aqueous Aloe Vera as emollient and absorbent of UV radiation to shield eye retina by topically applying said gel in the eye;
- US Patent No. 6,013,259 to de de Ia Pena, et al. relates to a process for obtaining Aloe Vera gel and the ophthalmic use of Aloe Vera gel in the treatment of dry eye syndrome; and US Patent No.
- 6,573,299 relates to a method for the prevention and treatment of orbital disorders associated with the aging eye in mammals by the application of a topical composition comprising a permeation enhancing amount of one or more penetration enhancers, and one or more bio-affecting agent which penetrate into the underlying tissues and into the vascular network of the orbit.
- ophthalmic compositions comprising Aloe Vera Gel preserved with the biguanide preservative Alexidine hydrochloride.
- ophthalmic preservatives such as those generally known to those of skill in the art may also he used to provide formulations in accordance with this invention.
- Such preservatives include benzalkonium chloride (BAK), sorbic acid/EDTA, H2O2 systems, Zinc preservative systems and stabilized hypochlorite preparations such as PURITE.
- Aloe Vera is a nutritional storehouse found naturally. Aloe Vera has a long history as a multipurpose folk remedy. Commercially, it can be separated into two products: gel and latex. Aloe Vera gel is the leaf pulp or mucilage and is a thin clear jelly-like substance that contains vitamin Bl, B2, B6, C; amino acids, and carbohydrate polymers such as mucopolysaccharides, glucomannans or pectic acid plus various other organic and inorganic compounds. Aloe Vera also works as an antioxidant and can be purchased from DSM Nutritional Products, Inc.
- Aloe Vera can accumulate in the anterior segment and moisturizes surrounding ocular tissues when administered topically. Aloe Vera also scavenges free radicals and other damaging compounds in the ocular tissues that alter cell membranes, tamper with DNA, and even cause cell death. Therefore, the present composition may protect ocular tissues from the damage of free radicals and improve the general health of the eye. Aloe vera gel may be present in a composition according to the invention in amounts ranging from about 1 to about 50 percent by weight.
- compositions of the invention herein also contain ophthalmically acceptable buffers such as Sodium borate/Boric acid.
- ophthalmically acceptable buffers suitable for use in the invention herein will be apparent to one having ordinary skill in the art.
- the composition further comprises ophthalmic demulcents such as any of the following, within the established concentrations for each ingredient: (a) Cellulose derivatives: (1) Carboxymethylcellulose sodium, 0.2 to 2.5 percent, (2) Hydroxyethyl cellulose, 0.2 to 2.5 percent, (3) Hypromellose, 0.2 to 2.5 percent and (4) Methylcellulose, 0.2 to 2.5 percent; (b) Dextran 70, 0.1 percent when used with another polymeric demulcent agent in this section; (c) Gelatin, 0.01 percent; (d) Polyols, liquids such as (1) Glycerin, 0.2 to 1 percent, (2) Polyethylene glycol 300, 0.2 to 1 percent, (3) Polyethylene glycol 400, 0.2 to 1 percent, (4) Polysorbate 80, 0.2 to 1 percent, (5) Propylene glycol, 0.2 to 1 percent, (e) Polyvinyl alcohol, 0.1 to 4 percent and (f) Povidone, 0.1 to 2 percent.
- Cellulose derivatives (1) Carboxymethylcellulose sodium, 0.2 to 2.5 percent,
- the composition further comprises balanced salts such as ZnC12 and MgC12.
- balanced salts such as ZnC12 and MgC12.
- Other inorganic materials such as HAP (tetrasodium etidronate (Monsanto)), tricalcium phosphate, dicalcium pyrophosphate, tetracalcium phosphate and octacalcium phosphate may also be included.
- composition may further comprise active agents such as any compound, composition of matter, or mixture thereof that can be delivered from the composition of the invention to produce a beneficial and useful result to the eye, especially an agent effective in obtaining a desired local or systemic physiological or pharmacological effect.
- active agents include: anesthetics and pain killing agents such as lidocaine and related compounds and benzodiazepam and related compounds; benzodiazepine receptor agonists such as abecarnil; GABA receptor modulators such as baclofen, muscimol and benzodiazepines; anti-cancer agents such as 5-fluorouracil, adriamycin and related compounds; anti-fungal agents such as fluconazole and related compounds; anti-viral agents such as trisodium phosphomonoformate, trifluorothymidine, acyclovir, ganciclovir, DDI and AZT; cell transport/mobility impending agents such as colchicine, vincristine, cytochalasin B and
- Such agents also include: neuroprotectants such as nimodipine and related compounds; antibiotics such as tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, gentamycin, and erythromycin; antiinfectives; antibacterials such as sulfonamides, sulfacetamide, sulfamethizole, sulfisoxazole; nitrofurazone, and sodium propionate; antiallergenics such as antazoline, methapyriline, chlo ⁇ heniramine, pyrilamine and prophenpyridamine; antiinflammatories such as hydrocortisone, hydrocortisone acetate, dexamethasone 21- phosphate, fluocinolone, medrysone, methylprednisolone, prednisolone 21 -phosphate, prednisol
- agents suitable for treating, managing, or diagnosing conditions in a mammalian organism may be placed in the inner core and administered using the sustained release drug delivery devices of the current invention.
- agents suitable for treating, managing, or diagnosing conditions in a mammalian organism may be placed in the inner core and administered using the sustained release drug delivery devices of the current invention.
- any pharmaceutically acceptable form of such a compound may be employed in the practice of the present invention, i.e., the free base or a pharmaceutically acceptable salt or ester thereof.
- Pharmaceutically acceptable salts include sulfate, lactate, acetate, stearate, hydrochloride, tartrate, maleate and the like.
- pH adjusting agents such as HCl and NaOH may also be used to adjust the pH of the final composition to between about 7.0 and about 7.4.
- Tonicity agents such as those commonly used in the art may be used to bring the osmolality of the final composition to between about 240 and about 260 mOsmo/Kg.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Disclosed herein are new formulations containing Aloe Vera preserved with a preservative seleted from the group consisting of biguadine preservative, benzalkonium chloride, sorbic acid/EDTA, H2O2 systems, Zinc preservative systems and stabilized hypochlorite preparations.. These formulations are useful as eye drops that provide high patient compliance as well as carriers for pharmaceuticals such as steroids and anti-allergy ophthalmic drugs.
Description
OPHTHALMIC COMPOSITIONS COMPRISING ALOE VERA Cross Reference
This application claims the benefit of Provisional Patent Application No. 60/638,735 filed December 22, 2005 and is incorporated herein by reference.
Disclosed herein are new formulations containing Aloe Vera. These formulations are useful as eye drops that provide high patient compliance as well as carriers for pharmaceuticals such as steroids and anti-allergy ophthalmic drugs.
The use of Aloe Vera in ophthalmic formulations is known. For example, US Patent No. 4,788,007 to Baron discloses a method of using ophthalmic dosage of aqueous Aloe Vera as emollient and absorbent of UV radiation to shield eye retina by topically applying said gel in the eye; US Patent No. 6,013,259 to de de Ia Pena, et al. relates to a process for obtaining Aloe Vera gel and the ophthalmic use of Aloe Vera gel in the treatment of dry eye syndrome; and US Patent No. 6,573,299 relates to a method for the prevention and treatment of orbital disorders associated with the aging eye in mammals by the application of a topical composition comprising a permeation enhancing amount of one or more penetration enhancers, and one or more bio-affecting agent which penetrate into the underlying tissues and into the vascular network of the orbit.
Despite these various patents, there is still a need for new ophthalmic formulations that offer higher patient compliance and greater universal appeal than traditional dry eye products. This is accomplished by using natural Aloe Vera with various polymer systems in a well-buffered solution. The formulation provides customers with an enhanced dry eye relief and other physiological benefits.
Disclosed herein are ophthalmic compositions comprising Aloe Vera Gel preserved with the biguanide preservative Alexidine hydrochloride. It will be
undisclosed that other ophthalmic preservatives such as those generally known to those of skill in the art may also he used to provide formulations in accordance with this invention. Such preservatives include benzalkonium chloride (BAK), sorbic acid/EDTA, H2O2 systems, Zinc preservative systems and stabilized hypochlorite preparations such as PURITE.
Aloe Vera is a nutritional storehouse found naturally. Aloe Vera has a long history as a multipurpose folk remedy. Commercially, it can be separated into two products: gel and latex. Aloe Vera gel is the leaf pulp or mucilage and is a thin clear jelly-like substance that contains vitamin Bl, B2, B6, C; amino acids, and carbohydrate polymers such as mucopolysaccharides, glucomannans or pectic acid plus various other organic and inorganic compounds. Aloe Vera also works as an antioxidant and can be purchased from DSM Nutritional Products, Inc.
It is known that Aloe Vera can accumulate in the anterior segment and moisturizes surrounding ocular tissues when administered topically. Aloe Vera also scavenges free radicals and other damaging compounds in the ocular tissues that alter cell membranes, tamper with DNA, and even cause cell death. Therefore, the present composition may protect ocular tissues from the damage of free radicals and improve the general health of the eye. Aloe vera gel may be present in a composition according to the invention in amounts ranging from about 1 to about 50 percent by weight.
In addition to Aloe vera gel, the compositions of the invention herein also contain ophthalmically acceptable buffers such as Sodium borate/Boric acid. Other ophthalmically acceptable buffers suitable for use in the invention herein will be apparent to one having ordinary skill in the art.
The composition further comprises ophthalmic demulcents such as any of the following, within the established concentrations for each ingredient: (a) Cellulose derivatives: (1) Carboxymethylcellulose sodium, 0.2 to 2.5 percent, (2) Hydroxyethyl cellulose, 0.2 to 2.5 percent, (3) Hypromellose, 0.2 to 2.5 percent and (4) Methylcellulose, 0.2 to 2.5 percent; (b) Dextran 70, 0.1 percent when used with another polymeric demulcent agent in this section; (c) Gelatin, 0.01 percent; (d) Polyols, liquids such as (1) Glycerin, 0.2 to 1 percent, (2) Polyethylene glycol 300, 0.2 to 1 percent, (3) Polyethylene glycol 400, 0.2 to 1 percent, (4) Polysorbate 80, 0.2 to 1 percent, (5) Propylene glycol, 0.2 to 1 percent, (e) Polyvinyl alcohol, 0.1 to 4 percent and (f) Povidone, 0.1 to 2 percent.
The composition further comprises balanced salts such as ZnC12 and MgC12. Other inorganic materials such as HAP (tetrasodium etidronate (Monsanto)), tricalcium phosphate, dicalcium pyrophosphate, tetracalcium phosphate and octacalcium phosphate may also be included.
The composition may further comprise active agents such as any compound, composition of matter, or mixture thereof that can be delivered from the composition of the invention to produce a beneficial and useful result to the eye, especially an agent effective in obtaining a desired local or systemic physiological or pharmacological effect. Examples of such agents include: anesthetics and pain killing agents such as lidocaine and related compounds and benzodiazepam and related compounds; benzodiazepine receptor agonists such as abecarnil; GABA receptor modulators such as baclofen, muscimol and benzodiazepines; anti-cancer agents such as 5-fluorouracil, adriamycin and related compounds; anti-fungal agents such as fluconazole and related compounds; anti-viral agents such as trisodium phosphomonoformate, trifluorothymidine, acyclovir,
ganciclovir, DDI and AZT; cell transport/mobility impending agents such as colchicine, vincristine, cytochalasin B and related compounds; antiglaucoma drugs such as beta- blockers: timolol, betaxolol, atenalol, etc; antihypertensives; decongestants such as phenylephrine, naphazoline, and tetrahydrazoline; immunological response modifiers such as muramyl dipeptide and related compounds; peptides and proteins such as cyclosporin, insulin, growth hormones, insulin related growth factor, heat shock proteins and related compounds; steroidal compounds such as dexamethasone, prednisolone and related compounds; low solubility steroids such as fluocinolone acetonide and related compounds; carbonic anhydrase inhibitors; diagnostic agents; antiapoptosis agents; gene therapy agents; sequestering agents; reductants such as glutathione; antipermeability agents; antisense compounds; antiproliferative agents; antibody conjugates; antidepressants; blood flow enhancers; antiasthmatic drugs; antiparasiticagents; nonsteroidal anti inflammatory agents such as ibuprofen; nutrients and vitamins: enzyme inhibitors: antioxidants; anticataract drugs; aldose reductase inhibitors; cytoprotectants; cytokines, cytokine inhibitors, and cytokine protectants; uv blockers; mast cell stabilizers; and anti neovascular agents such as antiangiogenic agents like matrix metalloprotease inhibitors.
Examples of such agents also include: neuroprotectants such as nimodipine and related compounds; antibiotics such as tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, gentamycin, and erythromycin; antiinfectives; antibacterials such as sulfonamides, sulfacetamide, sulfamethizole, sulfisoxazole; nitrofurazone, and sodium propionate; antiallergenics such as antazoline, methapyriline, chloφheniramine, pyrilamine and prophenpyridamine; antiinflammatories such as hydrocortisone, hydrocortisone acetate, dexamethasone 21-
phosphate, fluocinolone, medrysone, methylprednisolone, prednisolone 21 -phosphate, prednisolone acetate, fluoromethalone, betamethasone, loteprednol and triminolone; miotics and anti-cholinesterase such as pilocarpine, eserine salicylate, carbachol, di- isopropyl fluorophosphate, phospholine iodine, and demecarium bromide; mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxyamphetamine; sympathomimetics such as epinephrine; and prodrugs such as those described in Design of Prodrugs, edited by Hans Bundgaard, Elsevier Scientific Publishing Co., Amsterdam, 1985. In addition to the above agents, other agents suitable for treating, managing, or diagnosing conditions in a mammalian organism may be placed in the inner core and administered using the sustained release drug delivery devices of the current invention. Once again, reference may be made to any standard pharmaceutical textbook such as Remington's Pharmaceutical Sciences for the identity of other agents.
Any pharmaceutically acceptable form of such a compound may be employed in the practice of the present invention, i.e., the free base or a pharmaceutically acceptable salt or ester thereof. Pharmaceutically acceptable salts, for instance, include sulfate, lactate, acetate, stearate, hydrochloride, tartrate, maleate and the like. pH adjusting agents such as HCl and NaOH may also be used to adjust the pH of the final composition to between about 7.0 and about 7.4.
Tonicity agents such as those commonly used in the art may be used to bring the osmolality of the final composition to between about 240 and about 260 mOsmo/Kg.
Ηαe invention will be better understood by way of the following examples which are intended to illustrate but not limit the invention as defined by the claims contained herein. AU values are weight percent unless otherwise specified.
EXAMPLES:
Of the following examples, Examples 1, 2 and 4 have been prepared. The other examples are prophetic examples. EXAMPLE 1
EXAMPLE 2
EXAMPLE 3
EXAMPLE 4
EXAMPLE 5
EXAMPLE 6
EXAMPLE 7
Claims
1. Compositions comprising Aloe Vera Gel preserved with a preservative selected from the group consisiting of biguanide preservative, benzalkonium chloride, sorbic acid/EDTA, H2O2 systems, Zinc preservative systems and stabilized hypochlorite preparations; wherein the composition is intended for ophthalmic use.
2. The composition of claim 1 wherein the biguanide preservative is Alexidine hydrochloride.
3. The composition of claim 1 further comprising a demulcent selected from the group consisting of Cellulose derivatives such as Carboxymethylcellulose sodium, Hydroxyethyl cellulose, Hypromellose, and Methylcellulose; Dextran 70; Gelatin; liquid Polyols such as Glycerin, Polyethylene glycol 300, Polyethylene glycol 400, Polysorbate 80, Propylene glycol, Polyvinyl alcohol, Povidone and mixtures thereof.
4. The composition of claim 2 further comprising a demulcent selected from the group consisting of Cellulose derivatives such as Carboxymethylcellulose sodium, Hydroxyethyl cellulose, Hypromellose, and Methylcellulose; Dextran 70; Gelatin; liquid Polyols such as Glycerin, Polyethylene glycol 300, Polyethylene glycol 400, Polysorbate 80, Propylene glycol, Polyvinyl alcohol, Povidone and mixtures thereof.
5. The composition of Claim 1 further comprising an alginate.
6. The composition of Claim 2 further comprising an alginate.
7. The composition of Claim 3 further comprising inorganic molecules selected from the group consisting of ZnCl2 , MgCl2, HAP, tricalcium phosphate, dicalcium pyrophosphate, tetracalcium phosphate, octacalcium phosphate and mixtures thereof.
8. The composition of Claim 4 further comprising inorganic molecules selected from the group consisting of ZnCl2 , MgCl2, HAP, tricalcium phosphate, dicalcium pyrophosphate, tetracalcium phosphate, octacalcium phosphate and mixtures thereof.
9. The composition of Claim 7 further comprising an active agent.
10. The composition of Claim 8 further comprising an active agent.
11. The composition of Claim 9 wherein the active agent is Loteprednol etabonate.
12. The composition of Claim 10 wherein the active agent is Loteprednol etabonate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63873504P | 2004-12-22 | 2004-12-22 | |
| US60/638,735 | 2004-12-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006068899A2 true WO2006068899A2 (en) | 2006-06-29 |
| WO2006068899A3 WO2006068899A3 (en) | 2007-01-25 |
Family
ID=36087542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/045247 Ceased WO2006068899A2 (en) | 2004-12-22 | 2005-12-13 | Preserved ophthalmic compositions comprising aloe vera |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20060134060A1 (en) |
| WO (1) | WO2006068899A2 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007106723A3 (en) * | 2006-03-10 | 2007-11-15 | Bausch & Lomb | Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives |
| WO2008082948A3 (en) * | 2006-12-29 | 2008-10-02 | Bausch & Lomb | Ophthalmic alginate composition related methods of manufacture and methods of use |
| ES2366839A1 (en) * | 2010-04-12 | 2011-10-26 | Angel Nestares Guerrero | Composition for the care of contact lenses (Machine-translation by Google Translate, not legally binding) |
| LT6293B (en) | 2015-11-05 | 2016-08-10 | Uab "Origmed" | Pharmaceutical preparation for eyes with propolis and aloe vera and method of preparation thereof |
| CN107281557A (en) * | 2017-06-21 | 2017-10-24 | 江苏天眼医药科技股份有限公司 | A kind of production technology of contact lenses lubricating fluid |
| IT202200021852A1 (en) | 2022-10-21 | 2024-04-21 | Montefarmaco Otc S P A | Viscous ophthalmic liquid composition comprising natural gums and extracts |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060292105A1 (en) * | 2005-06-28 | 2006-12-28 | Lever O W Jr | Topical preservative compositions |
| US20110257125A1 (en) * | 2008-10-02 | 2011-10-20 | Rolf Schaefer | Mucomimetic compositions and uses therefore |
| ES2564560B1 (en) * | 2014-09-23 | 2017-03-13 | Agencia Pública Empresarial Sanitaria Hospital Alto Guadalquivir | Composition for the relief, improvement, prevention and / or treatment of dry eye syndrome |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4038692A1 (en) * | 1990-12-05 | 1992-06-11 | Heverhagen Ulrich | Agent for treating eye disorders esp. grey star - consists of demineralised sterilised water contg. urea and/or other substances, such as glycol, animal protein, plant extracts etc. |
| US6013259A (en) * | 1997-09-22 | 2000-01-11 | De De La Pena; Nuria E. A. C. | Patent on use of aloe vera ophthalmic solution for treatment of the dry eye syndrome, inflammations, ulcerations, alkaline or acid burns, infections, and cataracts |
| US5965088A (en) * | 1997-10-23 | 1999-10-12 | Lever; Andrea M. | Method for providing rapid disinfection of contact lenses |
| US6369112B1 (en) * | 1998-12-15 | 2002-04-09 | Bausch & Lomb Incorporated | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by tyloxapol |
| US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
| US6528464B1 (en) * | 2001-08-17 | 2003-03-04 | Bausch & Lomb Incorporated | Composition and method for inhibiting uptake of biguanide antimicrobials by hydrogels |
| MXPA04008171A (en) * | 2002-02-22 | 2004-11-26 | Pharmacia Corp | Ophthalmic formulation with gum system. |
-
2005
- 2005-12-13 WO PCT/US2005/045247 patent/WO2006068899A2/en not_active Ceased
- 2005-12-13 US US11/301,378 patent/US20060134060A1/en not_active Abandoned
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007106723A3 (en) * | 2006-03-10 | 2007-11-15 | Bausch & Lomb | Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives |
| WO2008082948A3 (en) * | 2006-12-29 | 2008-10-02 | Bausch & Lomb | Ophthalmic alginate composition related methods of manufacture and methods of use |
| ES2366839A1 (en) * | 2010-04-12 | 2011-10-26 | Angel Nestares Guerrero | Composition for the care of contact lenses (Machine-translation by Google Translate, not legally binding) |
| LT6293B (en) | 2015-11-05 | 2016-08-10 | Uab "Origmed" | Pharmaceutical preparation for eyes with propolis and aloe vera and method of preparation thereof |
| CN107281557A (en) * | 2017-06-21 | 2017-10-24 | 江苏天眼医药科技股份有限公司 | A kind of production technology of contact lenses lubricating fluid |
| IT202200021852A1 (en) | 2022-10-21 | 2024-04-21 | Montefarmaco Otc S P A | Viscous ophthalmic liquid composition comprising natural gums and extracts |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060134060A1 (en) | 2006-06-22 |
| WO2006068899A3 (en) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2346520B1 (en) | Curcuminoids and its metabolites for the application in ocular diseases | |
| EP2501388B1 (en) | Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions | |
| US20060148686A1 (en) | Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy | |
| US20240307306A1 (en) | Microemulsion for ophthalmic drug delivery | |
| US4730013A (en) | Biosoluble ocular insert | |
| JP7324566B2 (en) | Aqueous ophthalmic composition | |
| AU2003299696B2 (en) | Use of rimexolone in the treatment of dry eye | |
| EP1611879A1 (en) | Use of emulsions for intra- and periocular injection | |
| JP2019094356A (en) | Ophthalmologic aqueous composition | |
| CN115192517A (en) | Multifoam and eyelid application thereof | |
| EP4167965B1 (en) | Use of high molecular weight hyaluronic acid as ocular transporting vehicle | |
| US20060134060A1 (en) | Ophthalmic compositions comprising Aloe Vera | |
| EP4039248B1 (en) | Ophthalmic composition | |
| EP4670713A1 (en) | LIQUID DEPOSIT FOR NON-INVASIVE, DELAYED RELEASE OF ACTIVE INGREDIENTS TO THE EYE | |
| KR101433396B1 (en) | Flaxseed extract drug for eye application | |
| EP3675872B1 (en) | Compositions providing improved eye comfort | |
| EP4469047A2 (en) | Aqueous cevimeline compositions and methods of use | |
| WO2025144421A1 (en) | Aqueous nanomicelle ophthalmic formulations containing difluprednate | |
| WO2024110503A1 (en) | Methods for treating eyetear film deficiency | |
| CN111437252A (en) | Ophthalmic preparation containing erigeron breviscapus extract, preparation method and application | |
| HK1076248B (en) | Use of rimexolone in the treatment of dry eye |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05849531 Country of ref document: EP Kind code of ref document: A2 |